Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DPPTE-AuPET3 is an experimental gold–phospholipid complex in which a thiol-functionalized phospholipid (DPPTE) is coordinated to a triethylphosphine gold moiety (AuPEt3), designed as a glutathione peroxidase 4 (GPx4)–inhibiting gold salt phospholipid for cancer research, including mantle cell lymphoma models.[4] It is typically formulated within high-density lipoprotein (HDL)-mimetic nanoparticles to enhance tumor-selective delivery and exploit ferroptosis-like cell death pathways via GPx4 inhibition, but it is not a clinically developed pharmaceutical and is used only in preclinical laboratory studies.[4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DPPTE-AuPET3.